David F. Jenkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David F. Jenkins has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Beck
Wellcome Sanger Institute, Cambridge, United Kingdom
53 shared publications - Azadeh Cheraghchi-Bashi
AstraZeneca 1 Bioscience, Oncology R&D Cambridge, United Kingdom
53 shared publications - Brandon S. Willis
Oncology R&D, AstraZeneca, Waltham, Massachusetts
53 shared publications - Caitlin Hall
Wellcome Sanger Institute, Cambridge, United Kingdom
53 shared publications - Charlotte Tolley
Wellcome Sanger Institute, Cambridge, United Kingdom
53 shared publications - Claire Crafter
Oncology Targeted Discovery, R&D, AstraZeneca, Cambridge, UK
53 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic subtyping Supplementary Table 5: Representativeness of Study Participants Supplementary Figure 1: Study design Supplementary Figure 2: Plasma concentration of danvatirsen, acalabrutinib, and ACP-5862 (active metabolite of acalabrutinib) consistent with historical monotherapy data Supplementary Figure 3: EZB-related mutations by treatment response, number of cycles on treatment, cell-of-origin, and LymphGen cluster Supplementary Figure 4: STAT3 protein and ASO expression detection by IHC Supplementary Figure 5: Allele frequency over time for all patients by response Supplementary Figure 6: Copy number dynamics for all patients with available data by response Supplementary Figure 7: Peripheral blood analysis of gene expression associated with CD19+ B-cell signaling at baseline (A) and for baseline and longitudinal samples (B), and comparison of baseline gene expression of select B- and T-cell–specific genes in PBMCs in responders and nonresponders (C) Supplementary Figure 8: Peripheral blood analysis of gene expression associated with interferon-gamma signaling: baseline comparison (A) and baseline and longitudinal samples (B) Supplementary Figure 9: T-cell, B-cell, and NK-cell (TBNK) flow analysis: immunophenotyping in responders and nonresponders at baseline Supplementary Figure 10: Longitudinal immunophenotyping/immune cell population data (A) and percentage of CD4+ naïve T-cells among all CD4+ T cells (B) at each visit by treatment response Supplementary Figure 11: Pretreatment and on-treatment levels of cytokines/chemokines
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic subtyping Supplementary Table 5: Representativeness of Study Participants Supplementary Figure 1: Study design Supplementary Figure 2: Plasma concentration of danvatirsen, acalabrutinib, and ACP-5862 (active metabolite of acalabrutinib) consistent with historical monotherapy data Supplementary Figure 3: EZB-related mutations by treatment response, number of cycles on treatment, cell-of-origin, and LymphGen cluster Supplementary Figure 4: STAT3 protein and ASO expression detection by IHC Supplementary Figure 5: Allele frequency over time for all patients by response Supplementary Figure 6: Copy number dynamics for all patients with available data by response Supplementary Figure 7: Peripheral blood analysis of gene expression associated with CD19+ B-cell signaling at baseline (A) and for baseline and longitudinal samples (B), and comparison of baseline gene expression of select B- and T-cell–specific genes in PBMCs in responders and nonresponders (C) Supplementary Figure 8: Peripheral blood analysis of gene expression associated with interferon-gamma signaling: baseline comparison (A) and baseline and longitudinal samples (B) Supplementary Figure 9: T-cell, B-cell, and NK-cell (TBNK) flow analysis: immunophenotyping in responders and nonresponders at baseline Supplementary Figure 10: Longitudinal immunophenotyping/immune cell population data (A) and percentage of CD4+ naïve T-cells among all CD4+ T cells (B) at each visit by treatment response Supplementary Figure 11: Pretreatment and on-treatment levels of cytokines/chemokines
- Open Access
- 13 January 2025
- Published by Wiley in Genes, Brain and Behavior
- Vol. 24 (1) , e70009
Atp1a2 and Kcnj9 Are Candidate Genes Underlying Sensitivity to Oxycodone‐Induced Locomotor Activation and Withdrawal‐Induced Anxiety‐Like Behaviors in C57BL/6 Substrains
Opioid use disorder is heritable, yet its genetic etiology is largely unknown. C57BL/6J and C57BL/6NJ mouse substrains exhibit phenotypic diversity in the context of limited genetic diversity which together can facilitate genetic discovery. Here, we found C57BL/6NJ mice were less sensitive to oxycodone (OXY)‐induced locomotor activation versus C57BL/6J mice in a conditioned place preference paradigm. Narrow‐sense heritability of OXY‐induced locomotor activity traits ranged from 0.22 to 0.31, implicating suitability for genetic analysis. Quantitative trait locus (QTL) mapping in an F2 cross identified a chromosome 1 QTL explaining 7%–12% of the variance in OXY locomotion and anxiety‐like withdrawal in the elevated plus maze. A second QTL for EPM withdrawal behavior on chromosome 5 near Gabra2 (alpha‐2 subunit of GABA‐A receptor) explained 9% of the variance. To narrow the chromosome 1 locus, we generated recombinant lines spanning 163–181 Mb, captured the QTL for OXY locomotor traits and withdrawal, and fine‐mapped a 2.45‐Mb region (170.16–172.61 Mb). Transcriptome analysis identified five, localized striatal cis‐eQTL transcripts and two were confirmed at the protein level (KCNJ9, ATP1A2). Kcnj9 codes for a potassium channel (GIRK3) that is a major effector of mu opioid receptor signaling. Atp1a2 codes for a subunit of a Na+/K+ ATPase enzyme that regulates neuronal excitability and shows functional adaptations following chronic opioid administration. To summarize, we identified two candidate genes underlying the physiological and behavioral properties of opioids, with direct preclinical relevance to investigators employing these widely used substrains and clinical relevance to human genetic studies of opioid use disorder.
- 13 January 2025
- Published by Wiley in Genes, Brain and Behavior
- Vol. 24 (1) , e70009
Open AccessAtp1a2 and Kcnj9 Are Candidate Genes Underlying Sensitivity to Oxycodone‐Induced Locomotor Activation and Withdrawal‐Induced Anxiety‐Like Behaviors in C57BL/6 Substrains
Opioid use disorder is heritable, yet its genetic etiology is largely unknown. C57BL/6J and C57BL/6NJ mouse substrains exhibit phenotypic diversity in the context of limited genetic diversity which together can facilitate genetic discovery. Here, we found C57BL/6NJ mice were less sensitive to oxycodone (OXY)‐induced locomotor activation versus C57BL/6J mice in a conditioned place preference paradigm. Narrow‐sense heritability of OXY‐induced locomotor activity traits ranged from 0.22 to 0.31, implicating suitability for genetic analysis. Quantitative trait locus (QTL) mapping in an F2 cross identified a chromosome 1 QTL explaining 7%–12% of the variance in OXY locomotion and anxiety‐like withdrawal in the elevated plus maze. A second QTL for EPM withdrawal behavior on chromosome 5 near Gabra2 (alpha‐2 subunit of GABA‐A receptor) explained 9% of the variance. To narrow the chromosome 1 locus, we generated recombinant lines spanning 163–181 Mb, captured the QTL for OXY locomotor traits and withdrawal, and fine‐mapped a 2.45‐Mb region (170.16–172.61 Mb). Transcriptome analysis identified five, localized striatal cis‐eQTL transcripts and two were confirmed at the protein level (KCNJ9, ATP1A2). Kcnj9 codes for a potassium channel (GIRK3) that is a major effector of mu opioid receptor signaling. Atp1a2 codes for a subunit of a Na+/K+ ATPase enzyme that regulates neuronal excitability and shows functional adaptations following chronic opioid administration. To summarize, we identified two candidate genes underlying the physiological and behavioral properties of opioids, with direct preclinical relevance to investigators employing these widely used substrains and clinical relevance to human genetic studies of opioid use disorder.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic subtyping Supplementary Table 5: Representativeness of Study Participants Supplementary Figure 1: Study design Supplementary Figure 2: Plasma concentration of danvatirsen, acalabrutinib, and ACP-5862 (active metabolite of acalabrutinib) consistent with historical monotherapy data Supplementary Figure 3: EZB-related mutations by treatment response, number of cycles on treatment, cell-of-origin, and LymphGen cluster Supplementary Figure 4: STAT3 protein and ASO expression detection by IHC Supplementary Figure 5: Allele frequency over time for all patients by response Supplementary Figure 6: Copy number dynamics for all patients with available data by response Supplementary Figure 7: Peripheral blood analysis of gene expression associated with CD19+ B-cell signaling at baseline (A) and for baseline and longitudinal samples (B), and comparison of baseline gene expression of select B- and T-cell–specific genes in PBMCs in responders and nonresponders (C) Supplementary Figure 8: Peripheral blood analysis of gene expression associated with interferon-gamma signaling: baseline comparison (A) and baseline and longitudinal samples (B) Supplementary Figure 9: T-cell, B-cell, and NK-cell (TBNK) flow analysis: immunophenotyping in responders and nonresponders at baseline Supplementary Figure 10: Longitudinal immunophenotyping/immune cell population data (A) and percentage of CD4+ naïve T-cells among all CD4+ T cells (B) at each visit by treatment response Supplementary Figure 11: Pretreatment and on-treatment levels of cytokines/chemokines
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic subtyping Supplementary Table 5: Representativeness of Study Participants Supplementary Figure 1: Study design Supplementary Figure 2: Plasma concentration of danvatirsen, acalabrutinib, and ACP-5862 (active metabolite of acalabrutinib) consistent with historical monotherapy data Supplementary Figure 3: EZB-related mutations by treatment response, number of cycles on treatment, cell-of-origin, and LymphGen cluster Supplementary Figure 4: STAT3 protein and ASO expression detection by IHC Supplementary Figure 5: Allele frequency over time for all patients by response Supplementary Figure 6: Copy number dynamics for all patients with available data by response Supplementary Figure 7: Peripheral blood analysis of gene expression associated with CD19+ B-cell signaling at baseline (A) and for baseline and longitudinal samples (B), and comparison of baseline gene expression of select B- and T-cell–specific genes in PBMCs in responders and nonresponders (C) Supplementary Figure 8: Peripheral blood analysis of gene expression associated with interferon-gamma signaling: baseline comparison (A) and baseline and longitudinal samples (B) Supplementary Figure 9: T-cell, B-cell, and NK-cell (TBNK) flow analysis: immunophenotyping in responders and nonresponders at baseline Supplementary Figure 10: Longitudinal immunophenotyping/immune cell population data (A) and percentage of CD4+ naïve T-cells among all CD4+ T cells (B) at each visit by treatment response Supplementary Figure 11: Pretreatment and on-treatment levels of cytokines/chemokines
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Background: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib has activity in patients with R/R DLBCL, but durable responses are uncommon. STAT3 inhibition has demonstrated clinical activity in DLBCL. Methods: Final results of the Phase 1 study of acalabrutinib plus STAT3 inhibitor (danvatirsen; AZD9150) in patients with R/R DLBCL are reported. Danvatirsen 200 mg intravenous infusion (Days 1, 3, 5 [Cycle 1]; weekly infusions starting Day 8, Cycle 1) was administered in combination with oral acalabrutinib 100 mg twice daily until progressive disease (PD) or unacceptable toxicity. Primary endpoints were safety and tolerability. Secondary endpoints included efficacy, pharmacokinetics, and immunogenicity. Results: Seventeen patients received combination treatment. One dose-limiting toxicity (Grade 3 liver transaminase) occurred in one patient. The most common reason for treatment discontinuation was PD (65%). In evaluable patients (n=17), objective response rate was 24%; median duration of response was 1.9 months. All responders with available DLBCL cell-of-origin data were either activated B-cell or nongerminal center B-cell like subtype. Genetic subtype did not correlate with response. Baseline and longitudinal plasma cell-free DNA (cfDNA) concentrations were mostly higher in nonresponding patients. cfDNA changes were generally concordant with imaging. Pretreatment circulating B-cell levels were higher in responders versus nonresponders. Conclusion: Targeting both STAT3 and BTK in combination is safe and tolerable but efficacy is limited in R/R DLBCL. Results support evaluation of circulating tumor DNA as a biomarker for clinical response.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Background: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib has activity in patients with R/R DLBCL, but durable responses are uncommon. STAT3 inhibition has demonstrated clinical activity in DLBCL. Methods: Final results of the Phase 1 study of acalabrutinib plus STAT3 inhibitor (danvatirsen; AZD9150) in patients with R/R DLBCL are reported. Danvatirsen 200 mg intravenous infusion (Days 1, 3, 5 [Cycle 1]; weekly infusions starting Day 8, Cycle 1) was administered in combination with oral acalabrutinib 100 mg twice daily until progressive disease (PD) or unacceptable toxicity. Primary endpoints were safety and tolerability. Secondary endpoints included efficacy, pharmacokinetics, and immunogenicity. Results: Seventeen patients received combination treatment. One dose-limiting toxicity (Grade 3 liver transaminase) occurred in one patient. The most common reason for treatment discontinuation was PD (65%). In evaluable patients (n=17), objective response rate was 24%; median duration of response was 1.9 months. All responders with available DLBCL cell-of-origin data were either activated B-cell or nongerminal center B-cell like subtype. Genetic subtype did not correlate with response. Baseline and longitudinal plasma cell-free DNA (cfDNA) concentrations were mostly higher in nonresponding patients. cfDNA changes were generally concordant with imaging. Pretreatment circulating B-cell levels were higher in responders versus nonresponders. Conclusion: Targeting both STAT3 and BTK in combination is safe and tolerable but efficacy is limited in R/R DLBCL. Results support evaluation of circulating tumor DNA as a biomarker for clinical response.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic subtyping Supplementary Table 5: Representativeness of Study Participants Supplementary Figure 1: Study design Supplementary Figure 2: Plasma concentration of danvatirsen, acalabrutinib, and ACP-5862 (active metabolite of acalabrutinib) consistent with historical monotherapy data Supplementary Figure 3: EZB-related mutations by treatment response, number of cycles on treatment, cell-of-origin, and LymphGen cluster Supplementary Figure 4: STAT3 protein and ASO expression detection by IHC Supplementary Figure 5: Allele frequency over time for all patients by response Supplementary Figure 6: Copy number dynamics for all patients with available data by response Supplementary Figure 7: Peripheral blood analysis of gene expression associated with CD19+ B-cell signaling at baseline (A) and for baseline and longitudinal samples (B), and comparison of baseline gene expression of select B- and T-cell–specific genes in PBMCs in responders and nonresponders (C) Supplementary Figure 8: Peripheral blood analysis of gene expression associated with interferon-gamma signaling: baseline comparison (A) and baseline and longitudinal samples (B) Supplementary Figure 9: T-cell, B-cell, and NK-cell (TBNK) flow analysis: immunophenotyping in responders and nonresponders at baseline Supplementary Figure 10: Longitudinal immunophenotyping/immune cell population data (A) and percentage of CD4+ naïve T-cells among all CD4+ T cells (B) at each visit by treatment response Supplementary Figure 11: Pretreatment and on-treatment levels of cytokines/chemokines
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic subtyping Supplementary Table 5: Representativeness of Study Participants Supplementary Figure 1: Study design Supplementary Figure 2: Plasma concentration of danvatirsen, acalabrutinib, and ACP-5862 (active metabolite of acalabrutinib) consistent with historical monotherapy data Supplementary Figure 3: EZB-related mutations by treatment response, number of cycles on treatment, cell-of-origin, and LymphGen cluster Supplementary Figure 4: STAT3 protein and ASO expression detection by IHC Supplementary Figure 5: Allele frequency over time for all patients by response Supplementary Figure 6: Copy number dynamics for all patients with available data by response Supplementary Figure 7: Peripheral blood analysis of gene expression associated with CD19+ B-cell signaling at baseline (A) and for baseline and longitudinal samples (B), and comparison of baseline gene expression of select B- and T-cell–specific genes in PBMCs in responders and nonresponders (C) Supplementary Figure 8: Peripheral blood analysis of gene expression associated with interferon-gamma signaling: baseline comparison (A) and baseline and longitudinal samples (B) Supplementary Figure 9: T-cell, B-cell, and NK-cell (TBNK) flow analysis: immunophenotyping in responders and nonresponders at baseline Supplementary Figure 10: Longitudinal immunophenotyping/immune cell population data (A) and percentage of CD4+ naïve T-cells among all CD4+ T cells (B) at each visit by treatment response Supplementary Figure 11: Pretreatment and on-treatment levels of cytokines/chemokines
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 3 shows combination-cancer type pairs with 10 percent or more responder cell lines
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 3 shows combination-cancer type pairs with 10 percent or more responder cell lines
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Dose response matrix combination screening landscape. A, Schematic of screen and analysis. Created with BioRender.com. B, Overview of cell line cancer types. C, Drug combinations screened grouped by drug target pathways. D, Combo Emax for 755 cell lines screened with 109 combinations. White represents combination/cell line pairs not screened.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Dose response matrix combination screening landscape. A, Schematic of screen and analysis. Created with BioRender.com. B, Overview of cell line cancer types. C, Drug combinations screened grouped by drug target pathways. D, Combo Emax for 755 cell lines screened with 109 combinations. White represents combination/cell line pairs not screened.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 4 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Combination activity of selumetinib plus venetoclax or AZD5991 in AML. A and B, Combo Emax versus HSA scores in 19 AML cell lines exposed to selumetinib combined with (a) venetoclax or (b) AZD5991. C and D, NOMO1 growth inhibition and HSA excess to the combination of selumetinib with (c) venetoclax or (d) AZD5991. E and F, Western blot analysis for apoptosis markers in NOMO1 cells following time course treatment with selumetinib (300 nmol/L) combined with (e) venetoclax (300 nmol/L) or (f) AZD5991 (100 nmol/L). G, Tumor growth in NOMO1 xenografts treated with selumetinib, AZD5991, or venetoclax alone or in combination for 28 days (n = 5 each arm). Control and monotherapy experimental arms were halted once the maximum permitted tumor volume (2,000 cm3) was reached. Data are plotted as mean tumor volume ± SEM.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Combination activity of selumetinib plus venetoclax or AZD5991 in AML. A and B, Combo Emax versus HSA scores in 19 AML cell lines exposed to selumetinib combined with (a) venetoclax or (b) AZD5991. C and D, NOMO1 growth inhibition and HSA excess to the combination of selumetinib with (c) venetoclax or (d) AZD5991. E and F, Western blot analysis for apoptosis markers in NOMO1 cells following time course treatment with selumetinib (300 nmol/L) combined with (e) venetoclax (300 nmol/L) or (f) AZD5991 (100 nmol/L). G, Tumor growth in NOMO1 xenografts treated with selumetinib, AZD5991, or venetoclax alone or in combination for 28 days (n = 5 each arm). Control and monotherapy experimental arms were halted once the maximum permitted tumor volume (2,000 cm3) was reached. Data are plotted as mean tumor volume ± SEM.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S11 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 11 lists combination drug categories
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 11 lists combination drug categories
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S18 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 18 shows drug response data for single agents and combination treatments
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S18 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 18 shows drug response data for single agents and combination treatments